Condition: Fanconi Anemia · Severe Marrow Failure · Myelodysplastic Syndrome (MDS) · Sponsor: Children's Hospital Medical Center, Cincinnati
The purpose of this study is to determine whether the use of lower doses of busulfan and the elimination of cyclosporine will further reduce transplant-related side effects for patients with Fanconi Anemia (FA). Patients will undergo a transplant utilizing mis-matched related or matched unrelated donors following a preparative regimen of busulfan, fludarabine, anti-thymocyte globulin and cyclophosphamide.
This description comes directly from the study's public registry record.
Jamie Wilhelm · (513)803-1102 · Jamie.Wilhelm@cchmc.org
Sara Loveless, RN · (513)803-7656 · Sara.Loveless@cchmc.org
Always discuss trial participation with your own doctor first.
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Completed |
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | Recruiting |
| Fred Hutchinson Cancer Research Center | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02143830